ClinicalTrials.gg
CompletedNCT02289417UCUpdated May 7, 2020Results posted

Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis

A Phase 2 interventional study of Apremilast and Placebo in Ulcerative Colitis, sponsored by Amgen. Completed at 99 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-05-07.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
170
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 615 studies in Colitis, Ulcerative with a site in United States — 116 open to participants now, 167 under way, 34 of them phase 3. Colitis, Ulcerative · United States.

Enrollment
160th of 499
170 · median 76
Started
2015
with 32 others
Phase 2
146 of 615
25 open now
Registered
206th of 615
by date

Among the 615 studies in Colitis, Ulcerative with a site in United States, this one is the 160th largest by enrollment of the 499 interventional ones that give a count, is one of 33 that started in 2015, is one of 146 in phase 2, and was the 206th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

116 of the 615 studies in Colitis, Ulcerative with a site in United States are open now. Recruiting first, the newest first:

111 more — sign in →

All 116 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 615 studies in Colitis, Ulcerative with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the clinical efficacy, safety and tolerability of apremilast (30 mg twice daily [BID] and 40 mg BID), compared with placebo, in participants with active Ulcerative Colitis (UC).

Read the detailed description

Approximately 165 participants (55 subjects per arm) will be randomized in a 1:1:1 ratio to receive oral apremilast (30 mg BID or 40 mg BID), or identically appearing placebo BID for up to 12 weeks, followed by 40 weeks of blinded treatment with apremilast (30 mg BID or 40 mg BID).

At the end of the Blinded Active-treatment Phase (Week 52), participants who have a Mayo endoscopy score ≤ 1 will have the opportunity to participate in the Extension Phase. Participants enrolled in the Extension Phase will receive apremilast for an additional 52 weeks (Weeks 52 to 104). With the implementation of Amendment 4, participants entering the Extension Phase will receive apremilast 30 mg BID. Subjects currently in the Extension Phase who are receiving apremilast 40 mg BID will be switched to 30 mg BID at the next scheduled visit.

03

Conditions studied

  • Ulcerative Colitis

Keywords

  • Ulcerative Colitis
  • Inflammatory Bowel Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must satisfy the following criteria to be enrolled in the study:

  • Male or female aged 18 and over at the time of signing the .
  • Must understand and voluntarily sign an informed consent form prior to any study related assessments/procedures being conducted.
  • Diagnosis of ulcerative colitis (UC) with a duration of at least 3 months prior to the Screening Visit..
  • Total Mayo Score (TMS) ≥ 6 to ≤ 11 (range: 0-12) at baseline, prior to randomization in the study.
  • Endoscopic subscore ≥ 2 (range: 0-3) on the Mayo score prior to randomization in the study.
  • Subjects must have had a therapeutic failure, been intolerant to, or have a to, at least one of the following: oral aminosalicylates (ie, 5-aminosalicylic acid [5-ASA] compounds or sulfasalazine [SSZ]), budesonide, systemic , or (eg, 6-mercaptopurine [6-MP], azathioprine [AZA], or methotrexate [MTX]).

Exclusion criteria

Exclusion Criteria:

The presence of any of the following will exclude a subject from enrollment:

  • Diagnosis of Crohn's disease, indeterminate colitis, ischemic colitis, microscopic colitis, radiation colitis or diverticular disease-associated colitis.
  • Ulcerative colitis restricted to the distal 15 cm or less (eg, ulcerative proctitis).
  • Subjects who have had surgery as a treatment for UC or who, in the opinion of the Investigator, are likely to require surgery for UC during the study.
  • Clinical signs suggestive of fulminant colitis or toxic megacolon.
  • Prior use of any tumor necrosing factor (TNF) inhibitor (or any biologic agent).
  • Prior use of mycophenolic acid, tacrolimus, sirolimus, cyclosporine or thalidomide.
  • Use of intravenous (IV) within 2 weeks of the Screening Visit.
  • Use of (AZA, 6-MP or MTX) within 8 weeks of the Screening Visit.
  • Use of topical treatment with 5-ASA or corticosteroid enemas or suppositories within 2 weeks of the Screening Visit.
  • History of any neurological, renal, hepatic, gastrointestinal, pulmonary, metabolic, cardiovascular, psychiatric, endocrine, hematological disorder or disease, or any other medical condition that, in the investigator's opinion, would preclude participation in the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
170 participants (actual)

Study arms

  • Experimental
    Apremilast 30 mg PO BID

    Apremilast 30 mg by mouth (PO) twice a day (BID) for 12 weeks After 12 weeks: * Participants who achieve at least a 20% decrease from baseline in the total Mayo score (TMS) will continue to receive apremilast 30 mg BID for an additional 40 weeks. (Wk 52) * Participants who do not achieve at least a 20% decrease from baseline in the TMS will receive apremilast 40 mg BID for an additional 40 weeks (Wk 52) After 52 weeks, participants who are eligible for the Extension Phase will continue to receive the same dose of apremilast assigned at Wk 12 (30 mg BID or 40 mg BID) for an additional 52 weeks (Wk 104)

    Drug: Apremilast

  • Experimental
    Apremilast 40 mg PO BID

    Apremilast 40 mg by mouth (PO) twice a day (BID) for 12 weeks After 12 weeks, participants assigned to the 40 mg BID dose of apremilast at baseline will continue to receive apremilast 40 mg BID for an additional 40 weeks (Wk 52) After 52 weeks, participants who are eligible for the extension Phase will continue to receive apremilast 40 mg BID for an additional 52 weeks (Wk 104)

    Drug: Apremilast

  • Placebo comparator
    Placebo BID

    Identically matching placebo by mouth (PO) twice a day (BID) for 12 weeks. After 12 weeks all participants randomized to placebo at baseline will be re-randomized to receive apremilast 30 mg or 40 mg BID for an additional 40 weeks (Wk 52) After Wk 52, participants who are eligible for the extension phase will continue to receive the same dose of apremilast assigned at Wk 12 (30 mg BID or 40 mg BID) for an additional 52 weeks (Wk 104)

    Drug: Apremilast · Drug: Placebo

Interventions

  • Also known as: CC-10004; Otezla

  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved a Clinical Remission by Total Mayo Score (TMS) at Week 12

    Clinical remission was defined as a total Mayo score ≤ 2 points, with no individual subscore exceeding 1 point. The TMS is an instrument designed to measure disease activity of UC. The Mayo score ranges from 0 to 12 points. It consists of 4 subscores, each graded from 0 to 3 with higher scores indicating more severe disease. * Stool Frequency Subscore (SFS) * Rectal Bleeding Subscore (RBS) * Endoscopy Subscore * Physician's Global Assessment (PGA). Two-sided 95% confidence intervals (CI) for the within-group percentages are based on the Wilson score method.

    Time frame: Week 12

Secondary outcomes

  1. Percentage of Participants Who Achieved a Clinical Response by Total Mayo Score and the Reduction in the Rectal Bleeding Subscore at Week 12

    Clinical response was defined as a decrease from baseline in the TMS of at least 3 points and at least 30%, along with a reduction in the rectal bleeding subscore (RBS) of at least 1 point or an absolute RBS of ≤ 1. The TMS is an instrument designed to measure disease activity of UC. The Mayo score ranges from 0 to 12 points. It consists of 4 subscores, each graded from 0 to 3 with higher scores indicating more severe disease. * Stool Frequency Subscore (SFS) * Rectal Bleeding Subscore * Endoscopy Subscore * Physician's Global Assessment (PGA) Rectal bleeding (subscore 0-3) was defined as: 0 = No blood seen 1. = Streaks of blood with stool less than half the time 2. = Obvious blood with stool 3. = Blood alone passes Two-sided 95% CI for the within-group percentages are based on the Wilson score method.

    Time frame: Week 12

  2. Percentage of Participants Who Achieved an Endoscopic Remission at Week 12

    An endoscopic remission was defined as a Mayo endoscopic subscore (MES) of 0 at Week 12. The MES subscore findings were defined as: 0 = Normal or inactive disease 1. = Mild Disease (erythema, decreased vascular pattern, mild friability) 2. = Moderate Disease (marked erythema, lack of vascular pattern, friability erosions) 3. = Severe Disease (spontaneous bleeding, ulceration) The endoscopy subscores consisted of findings that were centrally read through proctosigmoidoscopy, graded from 0 to 3 with higher scores indicating more severe disease. Two-sided 95% CIs for the within-group percentage were based on the Wilson score method.

    Time frame: Week 12

  3. Percentage of Participants Who Achieved an Endoscopic Response at Week 12

    An endoscopic response is defined as a decrease from baseline of at least 1 point in the MES at Week 12. The Mayo endoscopy subscore findings were defined as: 0 = Normal or inactive disease 1. = Mild Disease (erythema, decreased vascular pattern, mild friability) 2. = Moderate Disease (marked erythema, lack of vascular pattern, friability erosions) 3 = Severe Disease (spontaneous bleeding, ulceration). The endoscopy subscores consisted of findings that were centrally read through proctosigmoidoscopy, graded from 0 to 3 with higher scores indicating more severe disease. Two-sided 95% CIs for the within-group percentage were based on the Wilson score method.

    Time frame: Week 12

  4. Percentage of Participants Who Achieved a Rectal Bleeding Subscore (RBS) of ≤ 1 at Week 12

    The RBS was measured as: 0 = No blood seen 1. = Streaks of blood with stool less than half the time 2. = Obvious blood with stool most of the time 3. = Blood alone passes The daily bleeding score represents the most severe bleeding of the day. Two-sided 95% CI for the within-group proportions are based on the Wilson score method.

    Time frame: Week 12

  5. Percentage of Participants Who Achieved Clinical Remission in the Modified Mayo Subscore (MMS) at Week 12

    Clinical remission was defined as a modified Mayo score of ≤ 2, with no individual subscore \> 1, at Week 12. The MMS was based on a modification of the total Mayo score (TMS) which included the stool frequency, rectal bleeding, and endoscopic subscores of the TMS and excluded the Physician's Global Assessment (PGA) subscore, since this was a global measure that is subjective in nature. The MMS ranges from 0 to 9 points with higher scores indicating greater disease severity. The endoscopy subscores was centrally reviewed. Two-sided confidence intervals for the within-group percentage were based on the Wilson score method.

    Time frame: Week 12

  6. Percentage of Participants Who Achieved Clinical Response in the Modified Mayo Subscore (MMS) at Week 12

    Clinical response in the MMS was defined as a decrease from baseline in the MMS of at least 2 points and at least 25%, along with a reduction in the RBS of at least 1 point or an absolute RBS ≤ 1. The MMS was based on the stool frequency, rectal bleeding, and endoscopic subscores of the TMS and excluded the PGA subscore. The MMS ranges from 0 to 9 points with higher scores indicating greater disease severity. The RBS was measured as: 0 = No blood seen 1. = Streaks of blood with stool less than half the time 2. = Obvious blood with stool most of the time 3. = Blood alone passes The daily bleeding score represents the most severe bleeding of the day. The endoscopy subscores was centrally reviewed. Two-sided confidence intervals for the within-group percentage were based on the Wilson score method.

    Time frame: Week 12

  7. Percentage of Participants Who Achieved Clinical Remission in the Partial Mayo Subscore (PMS) With no Individual Subscore >1 at Week 8

    Clinical remission in the partial Mayo subscore was defined as a PMS of 2 points or lower, with no individual subscore \>1. The PMS is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 9 (severe disease) and is a composite of 3 subscores: Stool Frequency Subscore, Rectal Bleeding Subscore, and Physician's Global Assessment Subscore, each of which ranges from 0 (normal) to 3 (severe disease). Two-sided 95% CI for the within-group proportions are based on the Wilson score method.

    Time frame: Week 8

  8. Percentage of Participants Who Achieved Clinical Response in the Partial Mayo Subscore at Week 8

    Clinical response in the PMS was defined as a decrease from baseline in PMS of at least 2 points and at least 25%, with an accompanying decrease in the RBS of at least 1 point or an absolute RBS of 0 or 1. The PMS score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 9 (severe disease) and is a composite of 3 subscores: Stool Frequency Subscore, Rectal Bleeding Subscore, and Physician's Global Assessment Subscore, each of which ranges from 0 (normal) to 3 (severe disease). Two-sided 95% CI for the within-group proportions are based on the Wilson score method.

    Time frame: Week 8

  9. The Number of Participants Who Experienced Treatment Emergent Adverse Events (TEAEs) During the Placebo-Controlled Phase

    A TEAE was defined as any adverse event (AE) occurring or worsening on or after the first treatment of apremilast and up to 28 days after the last apremilast dose or the last follow-up date, whichever occurred earlier. A serious AE = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs was assessed by the investigator and based on the following scale: Mild = asymptomatic or mild symptoms; clinical or diagnostic observations only; Moderate = Symptoms cause moderate discomfort; Severe (could be non-serious or serious) = symptoms causing severe discomfort/pain

    Time frame: From the first dose of investigational product (IP) and no later than 28 days after the last dose of IP for those who had completed the study or discontinued (D/C) early; maximum duration of exposure to treatment was 12.00 weeks

  10. The Number of Participants Who Discontinued Apremilast Due to Treatment Emergent Adverse Events During the Placebo-Controlled Period

    A TEAE was defined as any AE occurring or worsening on or after the first treatment of apremilast and up to 28 days after the last apremilast dose or the last follow-up date, whichever occurred earlier. A serious AE = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs was assessed by the investigator and based on the following scale: Mild = asymptomatic or mild symptoms; clinical or diagnostic observations only; Moderate = Symptoms cause moderate discomfort; Severe (could be non-serious or serious) = symptoms causing severe discomfort/pain.

    Time frame: From the first dose of IP and no later than 28 days after the last dose of IP for those who had completed the study or discontinued early; median duration of exposure to treatment was 12.00 weeks

  11. The Number of Participants Who Experienced TEAEs During the Apremilast (APR) Exposure Period (Active Treatment Phase) Through Week 52

    A TEAE was defined as any AE occurring or worsening on or after the first treatment of apremilast and up to 28 days after the last apremilast dose or the last follow-up date, whichever occurred earlier. A serious AE = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs was assessed by the investigator and based on the following scale: Mild = asymptomatic or mild symptoms; clinical or diagnostic observations only; Moderate = Symptoms cause moderate discomfort; Severe (could be non-serious or serious) = symptoms causing severe discomfort/pain

    Time frame: From first dose of IP and no later than 28 days after last dose of IP for those who completed the active treatment phase or D/C early; median duration of exposure = 41.00, 44.15 and 40.00 weeks respectively for 30 mg, 40 mg and 30 mg/40 mg APR arms

  12. The Number of Participants Who Experienced TEAEs During Week 52 to Week 104 (Extension Phase)

    A TEAE was defined as any AE occurring or worsening on or after the first treatment of apremilast and up to 28 days after the last apremilast dose or the last follow-up date, whichever occurred earlier. A serious AE = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs was assessed by the investigator and based on the following scale: Mild = asymptomatic or mild symptoms; clinical or diagnostic observations only; Moderate = Symptoms cause moderate discomfort; Severe (could be non-serious or serious) = symptoms causing severe discomfort/pain

    Time frame: From the first dose of IP at Week 52 and no later than 28 days after the last dose of IP for those who completed the study or had discontinued early; median exposure of apremilast for the total apremilast group was 52 weeks.

07

Results

Posted Oct 29, 2018

Participant flow

The study was conducted at 61 sites in Australia (3 sites) and New Zealand (1 site); Bulgaria (6 sites), Czech Republic (2 sites), Hungary (3 sites), Poland (9 sites), Russia (1 site), and Ukraine (10 sites); Canada (2 sites) and United States (13 sites); and France (4 sites), Germany (1 site), Italy (4 sites), and the Netherlands (2 sites).

Placebo-Controlled Phase Weeks 0-12
Participant flow — Placebo-Controlled Phase Weeks 0-12
MilestonePlaceboApremilast 30 mgApremilast 40 mgPlacebo/Apremilast 30 mgPlacebo/Apremilast 40 mgApremilast 30 mg/Apremilast 40 mgApremilast 40 mg/ Apremilast 40 mgExtension Phase: Apremilast 30 mgExtension Phase Apremilast 40 mg
Started585755000000
Completed515352000000
Not completed743000000
Withdrew: Adverse event301000000
Withdrew: Withdrawal by subject132000000
Withdrew: Lost to follow-up010000000
Withdrew: Lack of efficacy300000000
Active Treatment Phase Weeks 12-52
Participant flow — Active Treatment Phase Weeks 12-52
MilestonePlaceboApremilast 30 mgApremilast 40 mgPlacebo/Apremilast 30 mgPlacebo/Apremilast 40 mgApremilast 30 mg/Apremilast 40 mgApremilast 40 mg/ Apremilast 40 mgExtension Phase: Apremilast 30 mgExtension Phase Apremilast 40 mg
Started04142262512700
Completed0393217207500
Not completed0210955200
Withdrew: Adverse event014221000
Withdrew: Pregnancy001000000
Withdrew: Lack of efficacy014623000
Withdrew: Withdrawal by subject001011000
Withdrew: Lost to follow-up000000100
Withdrew: Miscellaneous000100100
Extension Phase Weeks 52-104
Participant flow — Extension Phase Weeks 52-104
MilestonePlaceboApremilast 30 mgApremilast 40 mgPlacebo/Apremilast 30 mgPlacebo/Apremilast 40 mgApremilast 30 mg/Apremilast 40 mgApremilast 40 mg/ Apremilast 40 mgExtension Phase: Apremilast 30 mgExtension Phase Apremilast 40 mg
Started00000004554
Completed00000003848
Not completed000000076
Withdrew: Adverse event000000023
Withdrew: Lack of efficacy000000022
Withdrew: Withdrawal by subject000000021
Withdrew: Miscellaneous000000010

Outcome measures

PrimaryPercentage of Participants Who Achieved a Clinical Remission by Total Mayo Score (TMS) at Week 12

Clinical remission was defined as a total Mayo score ≤ 2 points, with no individual subscore exceeding 1 point. The TMS is an instrument designed to measure disease activity of UC. The Mayo score ranges from 0 to 12 points. It consists of 4 subscores, each graded from 0 to 3 with higher scores indicating more severe disease. * Stool Frequency Subscore (SFS) * Rectal Bleeding Subscore (RBS) * Endoscopy Subscore * Physician's Global Assessment (PGA). Two-sided 95% confidence intervals (CI) for the within-group percentages are based on the Wilson score method.

Time frame:
Week 12
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved a Clinical Remission by Total Mayo Score (TMS) at Week 12
Percentage of ParticipantsPlaceboApremilast 30 mgApremilast 40 mg
Percentage of Participants Who Achieved a Clinical Remission by Total Mayo Score (TMS) at Week 1212.1 (6.0 to 22.9)31.6 (21.0 to 44.5)21.8 (12.9 to 34.4)
Statistical analysis
  • Placebo vs Apremilast 30 mg · Cochran-Mantel-Haenszel · p = 0.0142 · Stratified difference: 19.2 · 95% CI 3.4 to 33.6Stratified difference in percentages is the weighted average of the treatment differences across the strata with the CMH weights, with 2-sided 95% CI based on the stratified Newcombe method.
  • Placebo vs Apremilast 40 mg · Cochran-Mantel-Haenszel · p = 0.2689 · Stratified difference: 7.7 · 95% CI -6.9 to 22.0Stratified difference in percentages is the weighted average of the treatment differences across the strata with the CMH weights, with 2-sided 95% CI based on the stratified Newcombe method
SecondaryPercentage of Participants Who Achieved a Clinical Response by Total Mayo Score and the Reduction in the Rectal Bleeding Subscore at Week 12

Clinical response was defined as a decrease from baseline in the TMS of at least 3 points and at least 30%, along with a reduction in the rectal bleeding subscore (RBS) of at least 1 point or an absolute RBS of ≤ 1. The TMS is an instrument designed to measure disease activity of UC. The Mayo score ranges from 0 to 12 points. It consists of 4 subscores, each graded from 0 to 3 with higher scores indicating more severe disease. * Stool Frequency Subscore (SFS) * Rectal Bleeding Subscore * Endoscopy Subscore * Physician's Global Assessment (PGA) Rectal bleeding (subscore 0-3) was defined as: 0 = No blood seen 1. = Streaks of blood with stool less than half the time 2. = Obvious blood with stool 3. = Blood alone passes Two-sided 95% CI for the within-group percentages are based on the Wilson score method.

Time frame:
Week 12
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved a Clinical Response by Total Mayo Score and the Reduction in the Rectal Bleeding Subscore at Week 12
Percentage of ParticipantsPlaceboApremilast 30 mgApremilast 40 mg
Percentage of Participants Who Achieved a Clinical Response by Total Mayo Score and the Reduction in the Rectal Bleeding Subscore at Week 1246.6 (34.3 to 59.2)61.4 (48.4 to 72.9)67.3 (54.1 to 78.2)
Statistical analysis
  • Placebo vs Apremilast 30 mg · Cochran-Mantel-Haenszel · p = 0.1224 · Stratified difference: 14.6 · 95% CI -3.6 to 31.5Stratified difference in percentages is the weighted average of the treatment differences across the strata with the CMH weights, with 2-sided 95% CI based on the stratified Newcombe method.
  • Placebo vs Apremilast 40 mg · Cochran-Mantel-Haenszel · p = 0.0401 · Stratified difference: 19.4 · 95% CI 1.1 to 36.0Stratified difference in percentages is the weighted average of the treatment differences across the strata with the CMH weights, with 2-sided 95% CI based on the stratified Newcombe method.
SecondaryPercentage of Participants Who Achieved an Endoscopic Remission at Week 12

An endoscopic remission was defined as a Mayo endoscopic subscore (MES) of 0 at Week 12. The MES subscore findings were defined as: 0 = Normal or inactive disease 1. = Mild Disease (erythema, decreased vascular pattern, mild friability) 2. = Moderate Disease (marked erythema, lack of vascular pattern, friability erosions) 3. = Severe Disease (spontaneous bleeding, ulceration) The endoscopy subscores consisted of findings that were centrally read through proctosigmoidoscopy, graded from 0 to 3 with higher scores indicating more severe disease. Two-sided 95% CIs for the within-group percentage were based on the Wilson score method.

Time frame:
Week 12
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved an Endoscopic Remission at Week 12
Percentage of ParticipantsPlaceboApremilast 30 mgApremilast 40 mg
Percentage of Participants Who Achieved an Endoscopic Remission at Week 123.4 (1.0 to 11.7)8.8 (3.8 to 18.9)7.3 (2.9 to 17.3)
Statistical analysis
  • Placebo vs Apremilast 30 mg · Cochran-Mantel-Haenszel · p = 0.2472 · Stratified difference: 5.2 · 95% CI -5.7 to 16.7Stratified difference in percentages is the weighted average of the treatment differences across the strata with the CMH weights, with 2-sided 95% CI based on the stratified Newcombe method.
  • Placebo vs Apremilast 40 mg · Cochran-Mantel-Haenszel · p = 0.4628 · Stratified difference: 3.1 · 95% CI -7.5 to 14.6Stratified difference in percentages is the weighted average of the treatment differences across the strata with the CMH weights, with 2-sided 95% CI based on the stratified Newcombe method.
SecondaryPercentage of Participants Who Achieved an Endoscopic Response at Week 12

An endoscopic response is defined as a decrease from baseline of at least 1 point in the MES at Week 12. The Mayo endoscopy subscore findings were defined as: 0 = Normal or inactive disease 1. = Mild Disease (erythema, decreased vascular pattern, mild friability) 2. = Moderate Disease (marked erythema, lack of vascular pattern, friability erosions) 3 = Severe Disease (spontaneous bleeding, ulceration). The endoscopy subscores consisted of findings that were centrally read through proctosigmoidoscopy, graded from 0 to 3 with higher scores indicating more severe disease. Two-sided 95% CIs for the within-group percentage were based on the Wilson score method.

Time frame:
Week 12
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved an Endoscopic Response at Week 12
Percentage of ParticipantsPlaceboApremilast 30 mgApremilast 40 mg
Percentage of Participants Who Achieved an Endoscopic Response at Week 1241.4 (29.6 to 54.2)73.7 (61.0 to 83.4)47.3 (34.7 to 60.2)
Statistical analysis
  • Placebo vs Apremilast 30 mg · Cochran-Mantel-Haenszel · p = 0.0005 · Stratified difference: 32.0 · 95% CI 13.8 to 47.4Stratified difference in percentages is the weighted average of the treatment differences across the strata with the CMH weights, with 2-sided 95% CI based on the stratified Newcombe method.
  • Placebo vs Apremilast 40 mg · Cochran-Mantel-Haenszel · p = 0.6878 · Stratified difference: 3.7 · 95% CI -14.4 to 21.5Stratified difference in percentages is the weighted average of the treatment differences across the strata with the CMH weights, with 2-sided 95% CI based on the stratified Newcombe method.
SecondaryPercentage of Participants Who Achieved a Rectal Bleeding Subscore (RBS) of ≤ 1 at Week 12

The RBS was measured as: 0 = No blood seen 1. = Streaks of blood with stool less than half the time 2. = Obvious blood with stool most of the time 3. = Blood alone passes The daily bleeding score represents the most severe bleeding of the day. Two-sided 95% CI for the within-group proportions are based on the Wilson score method.

Time frame:
Week 12
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved a Rectal Bleeding Subscore (RBS) of ≤ 1 at Week 12
Percentage of ParticipantsPlaceboApremilast 30 mgApremilast 40 mg
Percentage of Participants Who Achieved a Rectal Bleeding Subscore (RBS) of ≤ 1 at Week 1272.4 (59.8 to 82.2)84.2 (72.6 to 91.5)87.3 (76.0 to 93.7)
Statistical analysis
  • Placebo vs Apremilast 30 mg · Cochran-Mantel-Haenszel · p = 0.1388 · Stratified difference: 11.5 · 95% CI -4.1 to 26.1Stratified difference in percentages is the weighted average of the treatment differences across the strata with the CMH weights, with 2-sided 95% CI based on the stratified Newcombe method.
  • Placebo vs Apremilast 40 mg · Cochran-Mantel-Haenszel · p = 0.0788 (Stratification was based on baseline use of PO corticosteroids and previously used immunosuppressants (yes/no).) · Stratified difference: 13.5 · 95% CI -1.6 to 27.7Stratified difference in percentages is the weighted average of the treatment differences across the strata with the CMH weights, with 2-sided 95% CI based on the stratified Newcombe method.
SecondaryPercentage of Participants Who Achieved Clinical Remission in the Modified Mayo Subscore (MMS) at Week 12

Clinical remission was defined as a modified Mayo score of ≤ 2, with no individual subscore \> 1, at Week 12. The MMS was based on a modification of the total Mayo score (TMS) which included the stool frequency, rectal bleeding, and endoscopic subscores of the TMS and excluded the Physician's Global Assessment (PGA) subscore, since this was a global measure that is subjective in nature. The MMS ranges from 0 to 9 points with higher scores indicating greater disease severity. The endoscopy subscores was centrally reviewed. Two-sided confidence intervals for the within-group percentage were based on the Wilson score method.

Time frame:
Week 12
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved Clinical Remission in the Modified Mayo Subscore (MMS) at Week 12
Percentage of ParticipantsPlaceboApremilast 30 mgApremilast 40 mg
Percentage of Participants Who Achieved Clinical Remission in the Modified Mayo Subscore (MMS) at Week 1219.0 (10.9 to 30.9)43.9 (31.8 to 56.7)27.3 (17.3 to 40.2)
Statistical analysis
  • Placebo vs Apremilast 30 mg · Cochran-Mantel-Haenszel · p = 0.0046 · Stratified difference: 24.8 · 95% CI 7.5 to 40.1Stratified difference in percentages is the weighted average of the treatment differences across the strata with the CMH weights, with 2-sided 95% CI based on the stratified Newcombe method.
  • Placebo vs Apremilast 40 mg · Cochran-Mantel-Haenszel · p = 0.4476 · Stratified difference: 6.0 · 95% CI -9.8 to 21.6Stratified difference in percentages is the weighted average of the treatment differences across the strata with the CMH weights, with 2-sided 95% CI based on the stratified Newcombe method.
SecondaryPercentage of Participants Who Achieved Clinical Response in the Modified Mayo Subscore (MMS) at Week 12

Clinical response in the MMS was defined as a decrease from baseline in the MMS of at least 2 points and at least 25%, along with a reduction in the RBS of at least 1 point or an absolute RBS ≤ 1. The MMS was based on the stool frequency, rectal bleeding, and endoscopic subscores of the TMS and excluded the PGA subscore. The MMS ranges from 0 to 9 points with higher scores indicating greater disease severity. The RBS was measured as: 0 = No blood seen 1. = Streaks of blood with stool less than half the time 2. = Obvious blood with stool most of the time 3. = Blood alone passes The daily bleeding score represents the most severe bleeding of the day. The endoscopy subscores was centrally reviewed. Two-sided confidence intervals for the within-group percentage were based on the Wilson score method.

Time frame:
Week 12
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved Clinical Response in the Modified Mayo Subscore (MMS) at Week 12
Percentage of ParticipantsPlaceboApremilast 30 mgApremilast 40 mg
Percentage of Participants Who Achieved Clinical Response in the Modified Mayo Subscore (MMS) at Week 1246.6 (34.3 to 59.2)63.2 (50.2 to 74.5)67.3 (54.1 to 78.2)
Statistical analysis
  • Placebo vs Apremilast 30 mg · Cochran-Mantel-Haenszel · p = 0.0755 · Stratified difference: 16.7 · 95% CI -1.4 to 33.5Stratified difference in percentages is the weighted average of the treatment differences across the strata with the CMH weights, with 2-sided 95% CI based on the stratified Newcombe method.
  • Placebo vs Apremilast 40 mg · Cochran-Mantel-Haenszel · p = 0.0370 · Stratified difference: 19.8 · 95% CI 1.5 to 36.4Stratified difference in percentages is the weighted average of the treatment differences across the strata with the CMH weights, with 2-sided 95% CI based on the stratified Newcombe method.
SecondaryPercentage of Participants Who Achieved Clinical Remission in the Partial Mayo Subscore (PMS) With no Individual Subscore >1 at Week 8

Clinical remission in the partial Mayo subscore was defined as a PMS of 2 points or lower, with no individual subscore \>1. The PMS is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 9 (severe disease) and is a composite of 3 subscores: Stool Frequency Subscore, Rectal Bleeding Subscore, and Physician's Global Assessment Subscore, each of which ranges from 0 (normal) to 3 (severe disease). Two-sided 95% CI for the within-group proportions are based on the Wilson score method.

Time frame:
Week 8
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved Clinical Remission in the Partial Mayo Subscore (PMS) With no Individual Subscore >1 at Week 8
Percentage of ParticipantsPlaceboApremilast 30 mgApremilast 40 mg
Percentage of Participants Who Achieved Clinical Remission in the Partial Mayo Subscore (PMS) With no Individual Subscore >1 at Week 832.8 (22.1 to 45.6)47.4 (35.0 to 60.1)52.7 (39.8 to 65.3)
Statistical analysis
  • Placebo vs Apremilast 30 mg · Cochran-Mantel-Haenszel · p = 0.1167 · Stratified difference: 14.6 · 95% CI -3.3 to 31.4Stratified difference in percentages is the weighted average of the treatment differences across the strata with the CMH weights, with 2-sided 95% CI based on the stratified Newcombe method.
  • Placebo vs Apremilast 40 mg · Cochran-Mantel-Haenszel · p = 0.0534 · Stratified difference: 18.1 · 95% CI -0.3 to 34.9Stratified difference in percentages is the weighted average of the treatment differences across the strata with the CMH weights, with 2-sided 95% CI based on the stratified Newcombe method.
SecondaryPercentage of Participants Who Achieved Clinical Response in the Partial Mayo Subscore at Week 8

Clinical response in the PMS was defined as a decrease from baseline in PMS of at least 2 points and at least 25%, with an accompanying decrease in the RBS of at least 1 point or an absolute RBS of 0 or 1. The PMS score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 9 (severe disease) and is a composite of 3 subscores: Stool Frequency Subscore, Rectal Bleeding Subscore, and Physician's Global Assessment Subscore, each of which ranges from 0 (normal) to 3 (severe disease). Two-sided 95% CI for the within-group proportions are based on the Wilson score method.

Time frame:
Week 8
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved Clinical Response in the Partial Mayo Subscore at Week 8
Percentage of ParticipantsPlaceboApremilast 30 mgApremilast 40 mg
Percentage of Participants Who Achieved Clinical Response in the Partial Mayo Subscore at Week 848.3 (35.9 to 60.8)64.9 (51.9 to 76.0)81.8 (69.7 to 89.8)
Statistical analysis
  • Placebo vs Apremilast 30 mg · Cochran-Mantel-Haenszel · p = 0.0758 · Stratified difference: 16.6 · 95% CI -1.5 to 33.3Stratified difference in percentages is the weighted average of the treatment differences across the strata with the CMH weights, with 2-sided 95% CI based on the stratified Newcombe method.
  • Placebo vs Apremilast 40 mg · Cochran-Mantel-Haenszel · p = 0.0004 · Stratified difference: 32.5 · 95% CI 14.9 to 47.5Stratified difference in percentages is the weighted average of the treatment differences across the strata with the CMH weights, with 2-sided 95% CI based on the stratified Newcombe method.
SecondaryThe Number of Participants Who Experienced Treatment Emergent Adverse Events (TEAEs) During the Placebo-Controlled Phase

A TEAE was defined as any adverse event (AE) occurring or worsening on or after the first treatment of apremilast and up to 28 days after the last apremilast dose or the last follow-up date, whichever occurred earlier. A serious AE = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs was assessed by the investigator and based on the following scale: Mild = asymptomatic or mild symptoms; clinical or diagnostic observations only; Moderate = Symptoms cause moderate discomfort; Severe (could be non-serious or serious) = symptoms causing severe discomfort/pain

Time frame:
From the first dose of investigational product (IP) and no later than 28 days after the last dose of IP for those who had completed the study or discontinued (D/C) early; maximum duration of exposure to treatment was 12.00 weeks
Reported as:
Count of participants · Participants
The Number of Participants Who Experienced Treatment Emergent Adverse Events (TEAEs) During the Placebo-Controlled Phase
ParticipantsPlaceboApremilast 30 mgApremilast 40 mg
Any TEAE312836
Any IP-related TEAE121320
Any Severe TEAE401
Any Serious TEAE201
Any Serious IP-related TEAE000
Any TEAE Leading to IP Withdrawal501
Any TEAE Leading to IP Interruption100
Any TEAE Leading to Death000
SecondaryThe Number of Participants Who Discontinued Apremilast Due to Treatment Emergent Adverse Events During the Placebo-Controlled Period

A TEAE was defined as any AE occurring or worsening on or after the first treatment of apremilast and up to 28 days after the last apremilast dose or the last follow-up date, whichever occurred earlier. A serious AE = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs was assessed by the investigator and based on the following scale: Mild = asymptomatic or mild symptoms; clinical or diagnostic observations only; Moderate = Symptoms cause moderate discomfort; Severe (could be non-serious or serious) = symptoms causing severe discomfort/pain.

Time frame:
From the first dose of IP and no later than 28 days after the last dose of IP for those who had completed the study or discontinued early; median duration of exposure to treatment was 12.00 weeks
Reported as:
Count of participants · Participants
The Number of Participants Who Discontinued Apremilast Due to Treatment Emergent Adverse Events During the Placebo-Controlled Period
ParticipantsPlaceboApremilast 30 mgApremilast 40 mg
The Number of Participants Who Discontinued Apremilast Due to Treatment Emergent Adverse Events During the Placebo-Controlled Period501
SecondaryThe Number of Participants Who Experienced TEAEs During the Apremilast (APR) Exposure Period (Active Treatment Phase) Through Week 52

A TEAE was defined as any AE occurring or worsening on or after the first treatment of apremilast and up to 28 days after the last apremilast dose or the last follow-up date, whichever occurred earlier. A serious AE = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs was assessed by the investigator and based on the following scale: Mild = asymptomatic or mild symptoms; clinical or diagnostic observations only; Moderate = Symptoms cause moderate discomfort; Severe (could be non-serious or serious) = symptoms causing severe discomfort/pain

Time frame:
From first dose of IP and no later than 28 days after last dose of IP for those who completed the active treatment phase or D/C early; median duration of exposure = 41.00, 44.15 and 40.00 weeks respectively for 30 mg, 40 mg and 30 mg/40 mg APR arms
Reported as:
Count of participants · Participants
The Number of Participants Who Experienced TEAEs During the Apremilast (APR) Exposure Period (Active Treatment Phase) Through Week 52
ParticipantsApremilast 30 mgApremilast 40 mgApremilast 30 mg/Apremilast 40 mg
Any TEAE60678
Any Severe TEAE560
Any Serious TEAE681
Any TEAE Leading to Drug Withdrawal391
Any TEAE Leading to Drug Interruption140
Any TEAE Leading to Death000
SecondaryThe Number of Participants Who Experienced TEAEs During Week 52 to Week 104 (Extension Phase)

A TEAE was defined as any AE occurring or worsening on or after the first treatment of apremilast and up to 28 days after the last apremilast dose or the last follow-up date, whichever occurred earlier. A serious AE = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs was assessed by the investigator and based on the following scale: Mild = asymptomatic or mild symptoms; clinical or diagnostic observations only; Moderate = Symptoms cause moderate discomfort; Severe (could be non-serious or serious) = symptoms causing severe discomfort/pain

Time frame:
From the first dose of IP at Week 52 and no later than 28 days after the last dose of IP for those who completed the study or had discontinued early; median exposure of apremilast for the total apremilast group was 52 weeks.
Reported as:
Count of participants · Participants
The Number of Participants Who Experienced TEAEs During Week 52 to Week 104 (Extension Phase)
ParticipantsExtension Phase: Apremilast 30 mgExtension Phase: Apremilast 40 mg
Any TEAE1627
Any Severe TEAE10
Any Serious TEAE43
Any Serious IP-related TEAE01
Any TEAE Leading to IP Withdrawal21
Any TEAE Leading to IP Interruption10
Any TEAE Leading to Death00

Adverse events

Collected over From the first dose of IP and no later than 28 days after the last dose of IP for those who had completed the study or discontinued early. AEs are reported for the placebo-controlled phase from Week 0 to Week 12 and for the apremilast exposure period from Week 0 to Week 104.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo (Placebo Controlled Period)0/58 (0%)2/58 (3.4%)20/58 (34.5%)
Apremilast 30 mg (Placebo Controlled Period)0/57 (0%)0/57 (0%)26/57 (45.6%)
Apremilast 40 mg BID (Placebo Controlled Period)0/55 (0%)1/55 (1.8%)25/55 (45.5%)
Apremilast 30 mg (Apremilast Exposure Period)0/83 (0%)9/83 (10.8%)49/83 (59%)
Apremilast 40 mg (Apremilast Exposure Period)0/80 (0%)11/80 (13.8%)53/80 (66.3%)
Apremilast 30/40 mg (Apremilast Exposure Period)0/11 (0%)1/11 (9.1%)11/11 (100%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventPlacebo (Placebo Controlled Period)Apremilast 30 mg (Placebo Controlled Period)Apremilast 40 mg BID (Placebo Controlled Period)Apremilast 30 mg (Apremilast Exposure Period)Apremilast 40 mg (Apremilast Exposure Period)Apremilast 30/40 mg (Apremilast Exposure Period)
Inguinal herniaGastrointestinal disorders0/580/570/550/830/801/11
Colitis ulcerativeGastrointestinal disorders2/580/570/551/833/800/11
Renal colicRenal and urinary disorders0/580/570/551/832/800/11
PancreatitisGastrointestinal disorders0/580/571/550/831/800/11
Abdominal herniaGastrointestinal disorders0/580/570/550/831/800/11
Crohn's diseaseGastrointestinal disorders0/580/570/550/831/800/11
DiarrhoeaGastrointestinal disorders0/580/570/550/831/800/11
Epididymitis tuberculousInfections and infestations0/580/570/550/831/800/11
Rectal abscessInfections and infestations0/580/570/550/831/800/11
Epididymal neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/580/570/550/831/800/11
Most frequent other events
Showing 10 of 47
Most frequent other events
EventPlacebo (Placebo Controlled Period)Apremilast 30 mg (Placebo Controlled Period)Apremilast 40 mg BID (Placebo Controlled Period)Apremilast 30 mg (Apremilast Exposure Period)Apremilast 40 mg (Apremilast Exposure Period)Apremilast 30/40 mg (Apremilast Exposure Period)
HeadacheNervous system disorders4/5812/5714/5517/8325/802/11
NauseaGastrointestinal disorders5/583/576/558/839/803/11
VomitingGastrointestinal disorders1/582/572/553/833/803/11
AstheniaGeneral disorders2/583/571/555/833/802/11
DiarrhoeaGastrointestinal disorders2/581/570/555/836/802/11
PyrexiaGeneral disorders2/581/571/551/832/802/11
NasopharyngitisInfections and infestations1/584/572/557/838/802/11
DyspepsiaGastrointestinal disorders1/581/570/552/830/801/11
Decreased appetiteMetabolism and nutrition disorders1/582/571/552/833/801/11
Abdominal painGastrointestinal disorders1/583/570/554/833/801/11

Baseline characteristics

The intent to treat (ITT) population consisted of all participants who were randomized and received at least 1 dose of investigational product (IP).

Age, Continuous
Age, Continuous(Years)PlaceboApremilast 30 mgApremilast 40 mgTotal
Mean42.9 ± 14.0440.1 ± 13.5043.4 ± 14.9242.1 ± 14.15
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboApremilast 30 mgApremilast 40 mgTotal
Female25182164
Male333934106
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboApremilast 30 mgApremilast 40 mgTotal
Hispanic or Latino2158
Not Hispanic or Latino555446155
Unknown or Not Reported1247
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboApremilast 30 mgApremilast 40 mgTotal
Asian0011
White545245151
Other1113
Not Reported or Collected34815
Duration of Ulcerative Colitis
Duration of Ulcerative Colitis(Years)PlaceboApremilast 30 mgApremilast 40 mgTotal
Mean6.85 ± 7.0436.15 ± 5.4328.63 ± 10.2787.19 ± 7.832
Baseline Total Mayo Score (TMS)
Baseline Total Mayo Score (TMS)(units on a scale)PlaceboApremilast 30 mgApremilast 40 mgTotal
Mean8.2 ± 1.688.5 ± 1.628.1 ± 1.678.3 ± 1.65
Modified Mayo Score (MMS)
Modified Mayo Score (MMS)(units on a scale)PlaceboApremilast 30 mgApremilast 40 mgTotal
Mean6.1 ± 1.516.4 ± 1.486.0 ± 1.476.2 ± 1.49
Partial Mayo Score (PMS)
Partial Mayo Score (PMS)(units on a scale)PlaceboApremilast 30 mgApremilast 40 mgTotal
Mean5.6 ± 1.465.8 ± 1.445.5 ± 1.575.6 ± 1.49

3 further baseline measures are reported on the registry.

08

Study locations

99 sites
  • Digestive Health Specialists of The Southeast
    Dothan, Alabama 36305, United States
  • Southern California Research Institute Medical Group, Inc.
    Los Angeles, California 90045, United States
  • Connecticut Clinical Research Foundation
    Bristol, Connecticut 06010, United States
  • Consultants for Clinical Research of South Florida
    Boynton Beach, Florida 33426, United States
  • Avail Clinical Research, LLC
    DeLand, Florida 32720, United States
  • Precision Clinical Research, LLC
    Lauderdale Lakes, Florida 33319, United States
  • Pharmax Research Clinic, Inc.
    Miami, Florida 33126, United States
  • Gastroenterology Group of Naples
    Naples, Florida 34102, United States
  • Advanced Medical Research Center
    Port Orange, Florida 32127, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
  • University of Louisville
    Louisville, Kentucky 40202, United States
  • UMass Medical Center
    Worcester, Massachusetts 01655, United States
  • Clinical Research Institute of Michigan, LLC
    Chesterfield, Michigan 48047, United States
  • Center for Digestive Health Research
    Troy, Michigan 48098, United States
  • Gastrointestinal Associates PA
    Flowood, Mississippi 39232, United States
  • NYU Langone Long Island Clinical Research Associates
    Great Neck, New York 11021, United States
  • Consultants for Clinical Research
    Cincinnati, Ohio 45219, United States
  • Quality Medical Research
    Nashville, Tennessee 37211, United States
  • Digestive Research Center/ Gastroenterology Consultants of San Antonio
    Live Oak, Texas 78233, United States
  • Digestive Health Specialist of Tyler
    Pasadena, Texas 77505, United States
  • San Antonio Gastroenterology
    San Antonio, Texas 78229, United States
  • University of Utah
    Salt Lake City, Utah 84132, United States
  • Harborview Medical Center
    Seattle, Washington 98104, United States
  • University of Washington Medical Center
    Seattle, Washington 98195, United States
  • Concord Repatriation General Hospital
    Concord, New South Wales 2139, Australia
  • Liverpool Hospital
    Liverpool, New South Wales 2170, Australia
  • Mater Adult Hospital
    South Brisbane, Queensland 4101, Australia
  • Footscray Hospital
    Footscray, Victoria 3011, Australia
  • Royal Melbourne Hospital
    Parkville, Victoria 3050, Australia
  • Multiprofile Hospital for Active Treatment Kaspela
    Plovdiv, 4002, Bulgaria
  • Medical Center Asklepion - Humane Medicine Research EOOD
    Sofia, 1303, Bulgaria
  • University Multiprofile Hospital for Active Treatment ACIBADEM City Clinic Sofia
    Sofia, 1407, Bulgaria
  • University Multiprofile Hospital for Active Treatment Sveti Ivan Rilski EAD
    Sofia, 1431, Bulgaria
  • University Multiprofile Hospital for Active Treatment Tsaritsa Yoanna ISUL EAD
    Sofia, 1527, Bulgaria
  • Clinic of Gastroenterology
    Sofia, 1784, Bulgaria
  • Multiprofile Hospital for Active Treatment Sveta Marina EAD
    Varna, 9010, Bulgaria
  • Winnipeg Regional Health Authority - Health Sciences Centre
    Winnipeg, Manitoba R3A 1R9, Canada
  • Hamilton Health Sciences Corporation, McMaster University Medical Centre
    Hamilton, Ontario L8N 3Z5, Canada
  • Fakultni nemocnice u sv Anny v Brne
    Brno, 656 91, Czechia
  • Fakultni nemocnice Hradec Kralove
    Hradec Kralove, 500 05, Czechia
  • Hepato-Gastroenterologie HK, s. r. o.
    Hradec Králové, 500 12, Czechia
  • Nemocnice Slany
    Slany, 274 01, Czechia
  • Amiens University Hospital
    Amiens, 80054, France
  • Hopital Beaujon
    Clichy, 92110, France
  • CHRU Nantes
    Nantes, 602 00, France
  • CHU de Nice Archet I
    Nice, 06202, France
  • Centre Hospitalier Lyon Sud
    Pierre Bénite, 69495, France
  • Centre Hospitalier Universitaire de Saint Etienne
    Saint Priest en Jarez, 42055, France
  • CHRU Nancy
    Vandoeuvre les Nancy, 54511, France
  • DRK Kliniken Berlin Westend
    Berlin, 14050, Germany
  • Crohn-Colitis-Centre Rhein-Main
    Frankfurt, 60594, Germany
  • Universitatsklinikum Schleswig-Holstein
    Keil, 24105, Germany
  • Gastroenterologische Praxis Minden
    Minden, 32423, Germany
  • Pannónia Magánorvosi Centrum Kft.
    Budapest, 1136, Hungary
  • ENDOMEDIX Kft.
    Budapest, 1139, Hungary
  • Vasútegészségügyi Nonprofit Kiemelten Közhasznú Kft. Debreceni Egészségügyi Központja
    Debrecen, 4025, Hungary
  • Karolina Korhaz Rendelointezet
    Mosonmagyaróvár, 9200, Hungary
  • Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont
    Szeged, 6720, Hungary
  • Tolna Megyei Balassa Janos Korhaz
    Szekszárd, 7100, Hungary
  • Javorszky Odon Korhaz
    Vác, 2600, Hungary
  • Azienda Ospedaliero Universitaria Di Bologna Policlinico Sorsola Malpighi
    Bologna, 40138, Italy
  • IRCCS - Istituo Clinico Humanitas - Humanitas Cancer Center
    Milan, 20089, Italy
  • Azienda Ospedaliera Ospedali Riuniti Villa Sofia-Cervello
    Palermo, 90146, Italy
  • Fondazione PTV Policlinico Tor Vergata
    Roma, 00133, Italy
  • Complesso Integrato Columbus
    Roma, 00168, Italy
  • Universitair Medisch Centrum Groningen
    Groningen, 9713 GZ, Netherlands
  • Ikazia Ziekenhuis
    Rotterdam, 3083 AN, Netherlands
  • Auckland City Hospital
    Auckland, 1023, New Zealand
  • Christchurch Hospital
    Christchurch, 8011, New Zealand
  • Dunedin Hospital
    Dunedin, 9016, New Zealand
  • Waikato hospital
    Hamilton, 3204, New Zealand
  • Uniwersytecki Szpital Kliniczny w Bialymstoku
    Bialystok, 15-276, Poland
  • Osrodek Badan Klinicznych CLINSANTE S.C.
    Bydgoszcz, 85-794, Poland
  • Centrum Medyczne sw. Lukasza
    Czestochowa, 42 202, Poland
  • Economicus - NZOZ ALL-MEDICUS
    Katowice, 40 659, Poland
  • Endoskopia Sp. z o.o.
    Sopot, 81-756, Poland
  • Sonomed Sp. z o.o.
    Szczecin, 71-685, Poland
  • Gastromed Kopon Zmudzinski i Wspolnicy Sp. j. Specjalistyczne Centrum Gastrologii i Endoskopii Spec. Gabinety Lekarskie
    Torun, 40 659, Poland
  • Centrum Zdrowia Matki, Dziecka i Mlodziezy
    Warsaw, 00-632, Poland
  • Niepubliczny Zaklad Opieki Zdrowotnej VIVAMED
    Warszawa, 03-563, Poland
  • Lexmedica Drubajlo Hanna
    Wroclaw, 03-580, Poland
  • Ars Medica
    Wroclaw, 53-333, Poland
  • Republican Clinical Hospital
    Kazan, 420064, Russian Federation
  • Stolitsa-Medikl, LLC
    Moscow, 115088, Russian Federation
  • SEIHPE Rostov State Medical University of MoH of RF
    Rostov on Don, 344022, Russian Federation
  • Regional Clinical Hospital
    Saratov, 410053, Russian Federation
  • Russian Medical Military Academy na SMKirov
    St Petersburg, 129329, Russian Federation
  • Regional Clinical Hospital, Gastroenterology department, State Higher Education Institute Ivano-Frankivsk National Medical University
    Ivano-Frankivsk, 58001, Ukraine
  • Ivano-Frankivsk Regional Clinical Hospital
    Ivano-Frankivsk, 76008, Ukraine
  • Ivano-Frankivsk Central City Clinical Hospital
    Ivano-Frankivsk, 76018, Ukraine
  • Kharkiv City Clinical Hospital 2
    Kharkiv, 61037, Ukraine
  • Private Enterprise Private Manufacture Company Acinus
    Kirovograd, 25006, Ukraine
  • Kremenchuk City Hospital # 1 n.a O.T.Bohaievskyi
    Kremenchuk, 39617, Ukraine
  • Lviv Emergency Clinical Hospital, Therapeutics Department No. 1
    Lviv, 79059, Ukraine
  • Municipal Institution Odesa Regional Clinical Hospital
    Odesa, 65025, Ukraine
  • Central City Clinical Hospital
    Uzhgorod, 88000, Ukraine
  • Vinnytsia Regional Clinical Hospital n a M I Pyrohov
    Vinnytsia, 21018, Ukraine
  • Municipal Institution Zaporizhzhia
    Zaporizhzhia, 69600, Ukraine
09

References and documents

Publications

  • Danese S, Neurath MF, Kopon A, Zakko SF, Simmons TC, Fogel R, Siegel CA, Panaccione R, Zhan X, Usiskin K, Chitkara D. Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients With Active Ulcerative Colitis. Clin Gastroenterol Hepatol. 2020 Oct;18(11):2526-2534.e9. doi: 10.1016/j.cgh.2019.12.032. Epub 2020 Jan 8. PubMed 31926340 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2015 to primary completion in Sep 2017, 32 months.

Results were first posted in Oct 2018, 1 year 1 month after primary completion. A results delay was requested in Feb 2018.

Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's 32 months is above that.

Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2014
First posted
Nov 13, 2014
StartActual
Jan 8, 2015
Primary completionActual
Sep 25, 2017
CompletionActual
Jun 3, 2019
Results delay requested
Feb 28, 2018
Results first posted
Oct 29, 2018
Last update
May 7, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02289417
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Nov 13, 2014
Start date
Jan 8, 2015
Primary completion
Sep 25, 2017
Completion
Jun 3, 2019
Results posted
Oct 29, 2018
Last update
May 7, 2020

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apremilast

Start the discussion